Marin Nishimura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4028843/publications.pdf

Version: 2024-02-01

933447 888059 23 281 10 17 citations g-index h-index papers 23 23 23 446 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Current and Future Use of InsertableÂCardiacÂMonitors. JACC: Clinical Electrophysiology, 2018, 4, 1383-1396.	3.2	46
2	The Impact of Substance Abuse on Heart Failure Hospitalizations. American Journal of Medicine, 2020, 133, 207-213.e1.	1.5	44
3	Clinical Characteristics and Outcomes of Patients With Heart Failure and Methamphetamine Abuse. Journal of Cardiac Failure, 2020, 26, 202-209.	1.7	30
4	Left Atrial Appendage Electrical Isolation as a Target in Atrial Fibrillation. JACC: Clinical Electrophysiology, 2019, 5, 407-416.	3.2	20
5	Methamphetamineâ€Associated Heart Failure Hospitalizations Across the United States: Geographic and Social Disparities. Journal of the American Heart Association, 2021, 10, e018370.	3.7	19
6	Percutaneous left atrial appendage occlusion in atrial fibrillation patients with a contraindication to oral anticoagulation: a focused review. Europace, 2018, 20, 1412-1419.	1.7	17
7	The Confounding Effects of Non-cardiac Pathologies on the Interpretation of Cardiac Biomarkers. Current Heart Failure Reports, 2018, 15, 239-249.	3.3	17
8	Characteristics and Outcomes of Methamphetamine Abuse Among Veterans With Heart Failure. American Journal of Cardiology, 2019, 124, 907-911.	1.6	17
9	Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. American Journal of Cardiology, 2018, 121, 131-140.	1.6	15
10	Predictive Factors for Progression of Mitral Regurgitation in Asymptomatic Patients With Mitral Valve Prolapse. American Journal of Cardiology, 2019, 123, 1309-1313.	1.6	12
11	Reversal agents for direct oral anticoagulants: A focused review. International Journal of Cardiology, 2016, 223, 244-250.	1.7	10
12	Gender-Based Differences in Cardiac Resynchronization Therapy Response. Cardiac Electrophysiology Clinics, 2019, 11, 115-122.	1.7	7
13	An update on the use and discovery of prognostic biomarkers in acute decompensated heart failure. Expert Review of Molecular Diagnostics, 2019, 19, 1019-1029.	3.1	6
14	Systematic Assessment of the Impact of Ultrasound-Enhancing Agents upon Measurements of Cardiac Size and Function by Echocardiography. Journal of the American Society of Echocardiography, 2020, 33, 313-321.	2.8	6
15	Systolic dysfunction in patients with methamphetamine use and heart failure with preserved ejection fraction. International Journal of Cardiology, 2022, 348, 90-94.	1.7	6
16	Hypertrabeculation as a Noncompaction Phenotype in Dilated Cardiomyopathy Defined by Contrast Echocardiography. JACC: Cardiovascular Imaging, 2019, 12, 1287-1288.	5.3	3
17	Clinical factors associated with baseline history of atrial fibrillation and subsequent clinical outcomes following initial implantable cardioverterâ€defibrillator placement. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 542-550.	1.2	3
18	Reasons for and predictors of acute hospitalization versus elective outpatient implantable cardioverter-defibrillator implantation and subsequent differential clinical outcomes. Journal of Interventional Cardiac Electrophysiology, 2017, 50, 85-93.	1.3	1

#	Article	IF	CITATIONS
19	Predictors of rate-adaptive pacing in patients implanted with implantable cardioverter–defibrillator and subsequent differential clinical outcomes. Journal of Interventional Cardiac Electrophysiology, 2019, 55, 83-91.	1.3	1
20	Association of body mass index with cardiac resynchronization therapy intention and left ventricular lead implantation failure: insights from the NCDR implantable cardioverter-defibrillator registry. Journal of Interventional Cardiac Electrophysiology, 2020, 57, 279-288.	1.3	1
21	Pain at the Game: Spontaneous Coronary Artery Dissection. American Journal of Medicine, 2014, 127, 1160-1163.	1.5	0
22	Benefits of Contemporary Implantable Cardioverter Defibrillators in Patients With Improved Ejection Fraction: When Is the Most Clinically Relevant Time to Evaluate?. JAMA Cardiology, 2017, 2, 1397.	6.1	0
23	Letter by Aldaas et al Regarding Article, "Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study― Circulation, 2019, 139, 144-145.	1.6	0